

Database, 2020, 1–15 doi:10.1093/database/baaa074 Database tool



Database tool

# An informatics research platform to make public gene expression time-course datasets reusable for more scientific discoveries

Braja Gopal Patra<sup>1</sup>, Babak Soltanalizadeh<sup>1</sup>, Nan Deng<sup>1</sup>, Leqing Wu<sup>1</sup>, Vahed Maroufy<sup>1</sup>, Canglin Wu<sup>2</sup>, W. Jim Zheng<sup>3</sup>, Kirk Roberts<sup>3</sup>, Hulin Wu<sup>1,3,\*</sup> and Ashraf Yaseen<sup>1,\*\*</sup>

<sup>1</sup>Department of Biostatistics and Data Science, School of Public Health, The University of Texas Health Science Center at Houston, 1200 Pressler Street, Houston, TX 77030, USA, <sup>2</sup>TechWave International. Inc., Houston, TX, USA and <sup>3</sup>School of Biomedical Informatics, The University of Texas Health Science Center at Houston, 7000 Fannin St. Suite 600, Houston, TX 77030, USA

\*Corresponding author. Phone: 713/500-9586; Email: Hulin.Wu@uth.tmc.edu

\*\*Phone: 713/500-9583; Email: Ashraf.Yaseen@uth.tmc.edu

Citation details: Patra,B.G., Soltanalizadeh,B., Deng,N., *et al.*, An informatics research platform to make public gene expression time-course datasets reusable for more scientific discoveries. *Database* (2020) Vol. 00: article ID baaa074; doi:10.1093/database/baaa074

Received 14 February 2020; Revised 17 July 2020; Accepted 10 August 2020

# Abstract

The exponential growth of genomic/genetic data in the era of Big Data demands new solutions for making these data findable, accessible, interoperable and reusable. In this article, we present a web-based platform named Gene Expression Time-Course Research (GETc) Platform that enables the discovery and visualization of time-course gene expression data and analytical results from the NIH/NCBI-sponsored Gene Expression Omnibus (GEO). The analytical results are produced from an analytic pipeline based on the ordinary differential equation model. Furthermore, in order to extract scientific insights from these results and disseminate the scientific findings, close and efficient collaborations between domain-specific experts from biomedical and scientific fields and data scientists is required. Therefore, GETc provides several recommendation functions and tools to facilitate effective collaborations. GETc platform is a very useful tool for researchers from the biomedical genomics community to present and communicate large numbers of analysis results from GEO. It is generalizable and broadly applicable across different biomedical research areas. GETc is a user-friendly and efficient web-based platform freely accessible at http://genestudy.org/

### Introduction

Over the past few decades, substantial funding and resources have been invested to generate biomedical datasets at many levels, ranging from nucleic acid and gene level to population level, in order to understand, treat and prevent various diseases, and protect public health. Based on data sharing policies of National Institute of Health (NIH) and other government agencies, many of aforementioned datasets are required to be shared with the general research communities. Consequently, vast amounts of biomedical data are being accumulated in databases and data repositories. However, use or reuse of these existing datasets for research by third parties is still not common as expected.

Gene expression data from various diseases under different experimental conditions are mostly deposited in the NIH/NCBI-sponsored Gene Expression Omnibus (GEO) data repository (1). Like many of the biomedical databases, GEO was originally created as a data repository to comply with the data sharing policies. Often, these data sharing platforms are designed and organized for easy and convenient data submission by experimentalists, but not friendly for data retrieval and analysis. Further, it is not easy to identify the particular datasets to address a particular biological question for a specific disease from GEO, since the experimental design and study description are documented in an unstructured free text. Hence, it is necessary to use text mining and natural language processing (NLP) technologies to restructure the existing repository so that datasets can be findable, accessible and reusable.

This article describes a web-based platform that addresses the difficulties in finding, accessing, reusing biomedical datasets, specifically from GEO, as well as the difficulties in finding and forming collaborations. The novel platform, named as Gene Expression Time-Course Research (GETc) platform (http://genestudy.org/), is built on top of an analytical method based on the ordinary differential equation (ODE) model for analyzing time-course gene expression data. GETc offers the following services and functions:

- Hosts time-course gene expression datasets from GEO annotated with disease and cell types.
- User-friendly navigation and searching functions.
- Hosts analysis results of the time-course gene expression datasets produced by the ODE analytic pipeline.
- Recommends relevant datasets for users based on their research interests.
- Recommends relevant papers and collaborators for each dataset hosted in the platform.

The rest of the article is organized as follows: Section 2 discusses the background of the analytic pipeline and recommendation systems. Section 3.1 presents datasets used for developing the GETc platform. Section 3.2 describes the methodology used for analytic pipeline, recommendation systems and platform implementation. Section 4 describes and discusses the results. Finally, conclusions are presented in Section 5.

#### Background

In this section, we present the three main parts of our work, (i) repositories developed for archiving datasets in the biomedical domains and their metadata, (ii) an analytic pipeline developed for analyzing gene data and (iii) dataset, literature and collaborator recommendation systems.

#### Dataset repositories

It is a growing trend among the researchers to make their data publicly available for reproducibility and data reusability. Many repositories and knowledge bases have been established for different types of data in many domains. GEO(www.ncbi.nlm.nih.gov/geo/), UKBioBank(ww w.ukbiobank.ac.uk/), ImmPort(www.immport.org/home) and TCGA(portal.gdc.cancer.gov) are a few examples of repositories in the biomedical domain. DATA.GOV archives the U.S. Government's open data from agriculture, climate, education, etc. for research use. However, users from the biomedical community have to visit and search each repository separately to find data for their research, which can be time-consuming and hectic.

DataMed(datamed.org) started an initiative to solve the above issue for the biomedical community by combining biomedical repositories and enhancing the query searching using advanced NLP techniques (2, 3). DataMed indexes and searches diverse categories of biomedical datasets (3). DataCite is another data discovery index, which includes 16 187 835 works from many different domains (4). However, these repositories do not provide either insight of data or help to find collaborators, which are still challenging tasks to accomplish.

#### Analytic pipelines for gene expression data

The study of gene regulation related to different biological functions is critical to understand the underlying mechanism of each function, such as cell growth, division, development and response to environmental stimulus. In addition, gene regulatory networks (GRN) have been shown useful for investigating the interaction among genes involved in a biological process, or genes responsive to an external stimulus. There are many computational approaches in the literature for inferring GRNs from gene expression data; for example, information theory models (5-7), Boolean networks (8-11) and Bayesian networks (12–15). However, these approaches are either not efficient in describing dynamic regulations between genes or restricted to small-scale networks. Meanwhile, responses to environmental stimulus, such as immune response to viral infection or response to aberrant activation of a particular pathway, are dynamic processes and require deliberate analysis of time-course gene expression data, which in turn is an ultra-high dimensional problem and needs the use of advanced statistical and computational approaches developed. Therefore, we implement an alternative comprehensive approach that exploits ODE models and gene regulatory network analysis developed in (16-18). This model takes into account the dynamic and temporal behavior of genes, and learns the dynamic relation between genes, in the form of stimulator or inhibitor of each other. Genes (or probes) with significant expression level changes over time are identified as dynamic response genes. Then the top 3000 dynamic response genes are clustered into groups according to their expression pattern over time. Finally, a regulatory network is established by the ODE model (19).

#### Recommendation systems

A recommendation system is an enabling mechanism to overcome information overload. Literature in this area can be broadly grouped as content-based or collaborative filtering based recommendation systems. Next, we discuss literature related to developed recommendation systems.

#### Dataset recommendation

There are many dataset repositories in the biomedical domain and many datasets are added to each repository on a daily basis. For example, 34 datasets were added to GEO repository daily in 2019. Hence researchers are likely to be overwhelmed with the data available and they have to visit each repository for searching a dataset. The platforms like DataMed solved this problem and researchers only had to visit DataMed for searching the datasets. However, DataMed has not been updated recently. Again, the intent of search is always difficult to identify (20). A dataset recommendation system based on researcher's profile may be helpful for information filtering. There were a few experiments performed on data linking (21-23) where similar datasets were clustered together using different semantic features. Most of these works were on linking the datasets with similar datasets rather than a dataset recommendation.

#### Literature recommendation

The usefulness of the literature recommendation can be stated by the acceptance of Google Scholar, Semantic Scholar, PubMed, etc. The CiteSeer project (24, 25) was the first of its kind to start research paper recommendation. Later, many scientific article recommendation systems were developed. Science Concierge is a content-based article recommendation system using distributional semantics (LSA) and the relevance feedback (Rocchio algorithm). It recommends articles for any number of input articles based on the 2015 Society of Neuroscience Conference articles (26). (27) proposed a citation-based collaborative filtering recommendation system for research articles using Jaccard similarity. Similar article recommendation systems have been developed using TF-IDF (28), topic modeling (29) and citation or author network analysis (30). TF-IDF was the most frequently applied weighting scheme for recommendation tasks (25).

SciMiner is a web-based platform for identifying gene names in text based on user input and provides literature from MEDLINE for the corresponding gene (31). A content-based PubMed article recommendation system, PURE, was developed using Expectation Minimization (32) and it recommends articles to users based on their preferred articles. (33) developed a probabilistic topic-based model for content similarity called '*pmra*' on the publications from MEDLINE and this has been used as a related article search function in PubMed. Most of the proposed literature recommendation systems use embedding methods to convert text into vectors and calculate the similarity between articles.

Once a researcher finds a dataset suitable for his/her study, he/she may need literature available related to the dataset. A literature recommendation system for datasets may be a helpful tool for this scenario where researchers can get literature from PubMed for each dataset.

#### Collaborator recommendation

Academic collaborator recommendation has long been regarded as a useful application in the academic environment, which aims to find potential collaborators for a given researcher by exploiting big academic data. In the past few years, several works on collaborator recommendation have been proposed (34–37).

Mainly, co-author network information has been incorporated to enhance the collaboration recommendation (35, 37, 38). (38) proposed a random walk restart model on co-author order, latest collaboration time point and collaboration times. (37) developed a collaborator recommendation system using collaborative entity embedding developed using the topic words collected from the publications of researchers. The cross-domain collaborator recommender is another important aspect of this recommendation and (36) proposed a cross-domain collaborator recommendation using the co-author matching, topic matching and cross-domain topic learning.

(35) proposed CollabSeer based on the co-author network and lexical similarity. However, it is difficult for new researchers or students to get recommendation using the co-author network or lexical similarity as they do not have papers. (39) proposed a collaborator recommender for new researchers or students using input keywords, organizational relationship, ratings and activity level of the collaborators.

When a researcher finds suitable data for his/her study, the researcher may look for collaborators to work with on that dataset. In this scenario, a collaborator recommendation system for each dataset may be helpful.

#### Materials and methods

#### Data

#### GEO Metadata collection

GEO is one of the most popular public repositories for functional genomics data. As of 18 December 2019, there were 122 222 series of datasets available in GEO. Metadata of GEO datasets such as title, summary, date of publication and name of authors was collected from the GEO using a web crawler. The PMIDs of the articles associated with each dataset were also collected. Many datasets did not have associated articles.

Time-course dataset: This study was conducted for the time-course datasets from GEO, however, the time-course datasets were not identified explicitly in the GEO websites. The time-course datasets can be identified manually by reading the dataset descriptions or scanning the associated data with it which is a time-consuming and tedious task. A keyword-based NLP method was applied for identifying time-course datasets. We implemented a regular expression-based approach to extract the time point information from the GEO metadata. For example, some phrases like '12 time points', '7 developmental stages; harvest at 10 hrs, 12 hrs', etc. were used to extract the time point information. The regular expression-based system was able to identify 167 datasets out of 200 random datasets with an accuracy of 83.5%. Further, a total of 555 datasets were filtered manually from 862 datasets identified by the above system for processing. More details on identifying time-course datasets can be found in (40). Once the datasets are identified, the GSE number were fed to the pipeline (Section 3.2.1) and it automatically retrieved the data and metadata information corresponding to GSE numbers. In addition to the time points, diseases, organisms or/and cell types were identified from the title and summary of the datasets. MetaMap (41) applied to the metadata, and the Human Disease Ontology (DOID) terms were detected from the annotated text for each dataset (42). Further, datasets can be filtered using both the cell type and diseases.

#### **MEDLINE Articles**

For developing dataset recommender, we collected the researcher's publications from PubMed. MEDLINE articles were collected for developing literature and collaborator recommenders. MEDLINE articles were collected from PubMed which comprises more than 29 million biomedical and life science research articles. These articles consist of information such as title, abstract, authors, affiliations, Medical Subject Headings (MeSH) terms and publisher name.

However, the articles collected from PubMed contain a variety of topics related to biomedicine and life sciences which may not be suitable for building a recommendation system for datasets in GEO. Further, the articles before 1998 were removed as the research on micro-array data started during that year (43). The datasets that are related to gene expressions and articles collected from PubMed contain a variety of topics. Thus, a MeSH term-based filtering method was implemented to remove unrelated articles from the whole MEDLINE articles. The details of the filtering method can be found in (43). A total of 770 537 articles were utilized for developing literature and collaborator recommendations.

#### Methods

#### Analytic pipeline for time-course gene expression data

We integrated the series of statistical and modeling methods for the time-course gene expression data into an analytic pipeline (19) which includes eight steps as mentioned in Figure 1.

The final analysis results of the pipeline can be reported as the initial bioinformatics findings for narrowing down the analysis and framing scientific questions, toward new collaborative publications. We could apply the pipeline to each of the time-course gene expression datasets under one experimental or biological condition. Furthermore, simple comparison functions between two or more datasets across experimental conditions and/or from different studies are currently under development for the pipeline. We published the source code of the analytic pipeline, so others can use the pipeline and expand its functionalities.(github.com/j142857z/Pipeline (Original code)),(github.com/AutumnTail/Pipeline (Updated code)).

#### Recommendation systems

Data Recommendation: Data recommendation is an essential part of the GETc platform. The dataset



Figure 1. Time-course gene expression analytic pipeline.

recommendation function recommends datasets to researchers based on their publications. The datasets used for this recommendation system contain data not only from GEO but also from other sources such as TCGA, ArrayExpress, SRA and Clinical Trails. We used only textual information of datasets (title and summary) and publications (title and abstract).

A researcher may have multiple research interests. To identify the research interests, we implemented a nonparametric clustering algorithm named Dirichlet process mixture model (DPMM). More details on DPMM and its parameter tuning for obtaining better number of clusters can be found in (44). Each researcher had to provide name and curriculum vitae (CV)/list of publications to get dataset recommendation. Researcher's names were searched in PubMed to get publications (title, abstract, year of publication). This search may result publications from other researchers with the same name which was solved by searching the title of the publication from PubMed in the CV/list of publications provided by the researcher. Finally, publications of the authors were clustered using DPMM to obtain the research topics. For each topic, datasets can be recommended by calculating cosine similarity of research field/cluster vector and dataset vectors. The detailed methodology and evaluation can be found in our previous publication on dataset recommendation (44).

Literature Recommendation: The literature recommendation system recommends literature for datasets. The most similar literature for a dataset can be determined simply by comparing the cosine similarity of the dataset vector and paper vectors. For developing the literature recommendation system in GETc, we used BM25 as it resulted in better precision at 10 compared to other embedding methods such as TF-IDF, word2vec and doc2vec (43). Finally, we used the title based weighted re-ranking and text normalization methods to improve the retrieved results. The detailed methods, experiments and results can be found in our previous publication (43).

**Collaborator Recommendation:** For each dataset, the recommendation system suggests some collaborators based on the recommended literature. We can say that the authors

of the top similar literature for a dataset can be suitable collaborators to work with on that dataset. The authors of the similar articles may have experience working on the dataset and already published articles using it. Further, the collaborators may be recommended for each dataset by ranking the unique authors of the retrieved similar articles. For a dataset (d), the score for each unique author of similar articles can be calculated using Equation (1).

AuthorScore<sub>i</sub> = 
$$\sum_{j=0}^{n}$$
 SimScore<sub>j</sub> \* weight (1)

weight = 
$$\begin{cases} 0 \text{ if } A_i \notin P_j \\ 1 \text{ if } A_i \text{ is the first or last author in } P_j \\ 0.1 \text{ if } A_i \text{ is not first or last author in } P_j \end{cases}$$

where AuthorScore<sub>*i*</sub> is the score for *i*th author calculated over all the retrieved similar articles ( $P = P_0, P_1, ..., P_n$ ) for *d*. *n* is the number of total retrieved article for *d*. SimScore<sub>*i*</sub> is the similarity score of *d* and *j*th article ( $P_i$ ).

Higher weights were provided to the first and last authors of each similar article whereas less weights were provided to all other authors. Finally, the authors with the highest scores were recommended as the collaborators for d.

The top 1000 recommended publications from the above literature recommender for a single dataset were used for identifying collaborators for that dataset. Furthermore, authors' affiliations provided in papers were parsed using the *affiliation\_parser*(github.com/titipata/affiliation\_parser) package and the distance between the recommended collaborators' and the user's current location was calculated using *geopy*(geopy.readthedocs.io) package to show a distance-based relevance of user and collaborators.

# **GETc Platform**

In this work, we developed an interactive web-based platform, called GETc, to facilitate collaboration and sharing




Figure 2. High-level architecture of the GETc platform.

of the analytic results of our pipeline on time-course gene expression data from GEO to the general research community. We have identified 555 time-course gene expression datasets with more than 7 time points from GEO. We applied our analytic pipeline on 37 of those datasets (results in Section 4). The output of the analytic pipeline for each dataset is folder of files containing intermediate and final analytic results, tables, graphics/plots and documents. The output also includes an automatically generated analysis report for each dataset.

Platform users could interactively search, browse and identify particular datasets and corresponding results of interest. They can visualize and review the analysis results including figures and tables, which can be easily downloaded via the platform web-based user-interface. For the unprocessed time-course gene expression datasets included in the platform, users can request to execute the pipeline. The platform also provides its users with recommendations by employing the recommendation systems described in Section 3.2.2. It recommends literature for timecourse gene expression datasets, potential collaborators for extracting scientific insights from the analytic results. It also recommends datasets to researchers. Figure 2 shows the overview of GET c platform. GET c platform executes the tasks mentioned inside the green box.

Users of the platform can search for a time-course dataset using keywords and phrases and see the literature available, significant gene lists, gene clusters and prospective collaborators for that dataset. A screenshot of search and view dataset functionalities is shown in Figure 3. The dataset can be searched if any of the searched keywords matched with the dataset id, title, abstract or platform organism. The datasets retrieved can be filtered using disease or cell type provided on the left side tree view or right side pie charts. The disease types are extracted from human disease ontology (40).

## **Results and discussion**

The results of the analytic pipeline which we applied on 37 time-course gene expression cancer datasets from GEO are presented in Table A1. For each dataset with different conditions, the table shows the number of DRGs, number of GRMs, number of time points, cancer type, cell line, the organism, vitro or *ex vitro* or *in vitro* or *in vivo* and species (human or mouse/rats species). MCF10A, MCF7, HeLa and other widely used cell lines are tested in these datasets. These cells lines are originated from various types of cancers such as breast cancer, cervical cancer and leukemia. Also, treatments in these datasets target several essential cancer pathways, such as NFkB, EGFR and hedgehog. These classifications will help researchers perform meta-analyses to identify common/key genes and GRN in a certain type of cancer.

Evaluating recommendation systems are challenging because no benchmark nor prior true annotation exists for either dataset recommendation or dataset-driven literature recommendation. For that reason, we performed a manual evaluation by asking expert human judges to rate the recommendation of systems using one to three 'stars' scale based on the relevance (1: not relevant, 2: partially relevant, 3: most relevant).

We evaluated the recommendation systems using strict and partial precision at 10 (P@10). Strict considers only 3-star, while partial considers both 2- and 3-star results. The developed dataset recommendation system was evaluated with five judges who have worked on the datasets before. The system obtained P@10 (strict) and P@10 (partial) of 0.61 and 0.78, respectively. For the literature recommendation, we considered 36 datasets for evaluation and the human judges have already worked on these datasets earlier. The proposed system obtained 0.80 and 0.87 of P@10 (strict) and P@10 (partial), respectively.

No gold standard dataset for evaluating collaborator recommendation is available to date. Similar to literature recommendation, evaluating our collaborator recommendation system was a challenging task, as it requires time to work with collaborators and only then they can provide feedback for system's output. We are currently working with additional multiple collaborators to evaluate the output of the system and generate feedback that we can use to assess the system's quality in the future.

A screenshot of literature (top right corner) and collaborator (bottom right corner) recommendations for dataset GSE14 103 is provided in Figure 4. For a selected dataset on the platform UI, the literature recommendation system will generate a list of related papers recommended for users. The

Datasets Clear Filters Diseases	Search dat	asets by keywords, da	taset id, disea	se, celltype or full text			Q	Diseases
CellTypes	Displayir	ng 10 of 555 datase	ots					
	ID \$	Title 💠	Last Update $ arrow$	Disease 💠	Cell Type 💠	Time Points	Pipeline Results $\Rightarrow$ $\pm$	
	GSE14103	Synchronized HTC116 cells: time course	2013-06- 07	colorectal cancer		8	View Results	Cell Types
	GSE1640	Serial time induction by TPA on BCBL-1 cells in th	2012-03- 15	lymphoma;kaposi's sarcoma;sarcoma		10	View Results	
	CSE17018	Detection of Treatment-Induced Changes in Signalin	2013-06- 13	gist;stromal tumors		9	View Results	
	GSE1864	A genomic view of estrogen actions in human breast	2012-03- 15	breast cancer		11	View Results	
	GSE18684	Fine mapping of androgen regulated genes in LNCaP	2013-02- 15	prostate cancer		28	View Results	
	GSE20988	Cooperative Epigenetic Modulation by Cancer Amplic	2013-06- 13	lymphoma;hodgkin's lymphoma;b-cell lymphoma	Bcell	8	View Results	

Figure 3. Search and view datasets in GETc research platform.

Search Index	٩	Dataset: GSE14103	GEO Rei	GEO				Related Papers
GSE14103		Datalet GSE 14105	dro me	alo -				1. Nocodazole treatment decreases expression of plu
HCT116		Title: Synchronize	d HTC116 cells	s: time course				potency markers Nanog and Oct4 in human embry 2. DMSO is a strong inducer of DNA hydroxymethyla
		Summary: Analysis of s	synchronized H	CT116 cells at various	time points up to 10 hours fo	ollowing treatment with I	DMSO or Nocodazole.	on in pre-osteoblastic MC3T3-E1 cells.
								<ol> <li>Marmosot induced pluripotent stem cells: Robust r eural differentiation following pretreatment with di</li> </ol>
								<ol> <li>Synchronized oscillation of the segmentation clock gene in vertebrate development.</li> </ol>
		Conditions Summ	tary					<ol> <li>Imiguimod treatment effectively reduces the perce tage of viable cells in a cervical carcinoma cell line b</li> </ol>
						A of Tax DDCs for		<ul> <li>6. Diapace prevention effect of Bombyx mori by dim ethyl sulfoxide.</li> </ul>
		Condition		# of time points	# of DRGs	# of Top DRGs for comparison	# of GRMs	<ol> <li>High-throughput single-cell quantification using si mple microwell-based cell docking and programmab.</li> </ol>
		HCT11	6	8	6295	3000	33	<ul> <li>8. Branching process deconvolution algorithm reveals a detailed cell-cycle transcription program.</li> </ul>
								<ul> <li>9. Citrullinated histone H3: a novel target for the trea ment of sepsis.</li> </ul>
								<ol> <li>Dimethyl sulloxide inhibits spontaneous diabetes and autoimmune recurrence in non-obese diabetic</li> </ol>
								Load More
		Pipeline Steps of Cor	ndition: HCT1	16				
								Related Authors 👍
		Step 2: Preprocess	Step 3: DRO	Gs Step 4: GRMs	Step 5: Annotate GRMS	Step 6: GRNs St	tep 7: Analyse GRNs	1. A Kallas: 5514 miles: Paper Link Tartu. Estonia
							Download Data 🛛 🛛 View D	2. T Maimets: 5514 miles: Paper Link Tartu, Estonia
								3. R Thaler: 5615 miles: Paper Link Vienna, Austria
				_				4. F Varga; 5615 miles; Paper Link
				Expre	ession of a	II genes		Vienna, Austria 5. Z. Qiu: 751 miles; Paper Link
								United States

Figure 4. A screenshot of recommended literature and collaborators for GSE14103.

recommended list of collaborators can be sorted by name or distance. We have a plan to implement a search function which will allow users to search for collaborators based on the preferred city.

We believe the functions of GETc are very useful for researchers from the biomedical genomics community to present and communicate large numbers of analysis results. In addition to datasets from GEO, we are currently expanding the platform with new time-course datasets from other repositories such as TCGA, SRA and ImmPort. We applied the ODEs in the process of constructing the high-dimensional gene regularity network where having at least 8-time points was essential for the identifiability of the corresponding model. Thus, only datasets with more than or equal to 8-time points can be processed with our pipeline.

#### Conclusion

In this work, we developed a novel research platform called GETc for sharing data and analytic results of timecourse gene expression datasets from GEO to improve the dataset reusability. It is built on top of an analytical method based on the ODE model for analyzing time-course gene expression data. GETc platform provides means to efficiently search and retrieve data, results, and facilitate collaboration through recommendation of related literature and potential collaborators corresponding to datasets. This platform also hosts a dataset recommendation system which will help researchers in biomedical domain to search datasets based on their publications. This will hopefully lead to better data reuse experience. We believe that the proposed novel idea and computational platform could also be applied to other types of data from different databases or data repositories.

#### Acknowledgement

We thank Dr H.M and other members from GEO Big Data Working Group at the Center for Big Data in Health Sciences (CBD-HS) for suggestions and comments on designing platform that greatly improved the website.

#### Funding

This project is mainly supported by the Center for Big Data in Health Sciences (CBD-HS) at School of Public Health, University of Texas Health Science Center at Houston (UTHealth), and partially supported by grants National Institute of Health (R01 AI087135, 1R01AG066749-01, 1UL1TR003167-01), Cancer Prevention and Research Institute of Texas (CPRIT RP170668) at UTHealth.

Conflicts of interest. None declared.

.×	Res
end	A1.
dd	able
4	ц

6	
Mus	
∠ z`	
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	
icus	
veg	
nor	
ns I	
Ratt	
Š,	
SP, Homo sapiens: HS, Ra	
ien	
sap	
υu	
Ē	
SP,	
SS:	
pecie	
s,	
<u>≥</u>	
N N	
 2	
ev S	
itro	
: ivr, ex vitro: evv, in vivo: ivv, Sp	
,r, é	
ö	
n vitr	
Ŀ.	
sm,	
Jani	
Org	
ö	
<u>9</u>	
ets	
atas	
er d	
ance	
e Cô	
ţ	
ron	
ics f	
tisti	
sta	
ults	Ê
Rest	≥ N
Ľ.	us:
le A	scul
Tab	Mu

SL	GEO accession	Time point	Cancer type	Cell line	ORG	SP	Condition	# of DRG	# of GRM
	GSE1864	11	Breast cancer	ZR-75.1	ivr	HS	$17\beta$ -estradiol	1272	85
							$17\beta$ -estradiol (dye	1145	34
							swap)		
2	GSE3113	8	Colorectal carcinoma	EcR-RKO/KLF4	ivr	HS	Ponesterone	3349	44
							Control	1589	50
3	GSE770	10	Prostate adenocarcinoma	LNCaP C4-2	ivr	HS	Irradiation	4227	72
4	GSE1640	10	Kaposi's sarcoma	BCBL-1	ivr	HS	Cidofovir rep1	473	146
							Cidofovir rep2	453	137
							Cidofovir rep3	301	164
							Control rep1	643	125
							Control rep2	504	121
							Control rep3	568	142
5	GSE9048	14	N/A	Embryonic stem	ivr	MM	HDRep1	21 349	30
							HDRep2	21 349	37
							HD_LIF	20 209	36
9	GSE9854	10	Osterosarcoma	U2OS	ivr	HS	GFP	6400	84
							HIC1	7062	61
7	GSE14103	8	Colorectal carcinoma	HCT116	ivr	HS	Nocodazole	6295	33
		6					Imatinib mesylat	13 121	42
							Rep1		
8	GSE17018	6	stomach	GIST-T1	ivr	HS	Imatinib mesylat	13 121	42
							Rep2		
		8					Imatinib mesylat	23 002	34
							Rep3		
6	GSE20361	8	Breast cancer	MCF-7	ivr	HS	$17\beta$ -estradiol		20
10	GSE20988	8	Mediastinal (thymic) large B-cell	K1106	ivr	HS	JAK2 inhibitor	4766	46
			lymphoma						
11	GSE22955	16	Breast cancer	SUM-225	ivr	HS	HER-2 inhibitor	11 725	84
							CP724,714		
12	GSE23135	16	Breast cancer	MCF-10A	ivr	HS	Gfitinib	10 046	50
13	GSE23136	16	Breast cancer	MCF-10HER-2	ivr	HS	Gfitinib	$12 \ 184$	49

StrengthGallonForCandinon $e^{\sigma}$ (PBK) $e^{\sigma}$ (PBK) $e^{\sigma}$ 14GST185423Prostare alencurrinomLNCaPivHSR818, Rep:166672929Prostare alencurrinomLNCaPivHSR818, Rep:162792929Prostare alencurrinomLNCaPivHSR818, Rep:162792929Prostare alencurrinomLNCaPivHSR818, Rep:162792929Prostare alencurrinomLNCaPivHSR818, Rep:16279292929Prostare alencurrinomNCF7ivHSR818, Rep:1627929292929292929292929292929292929292929292029292929292929292920292929292929292929202929292929292929292029292929292929292920292929292929292929212929292929292929292129292929292929 <td< th=""><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></td<>										
accesion         point         1         Accesion         point         866           GSE1864         28         Prostate adenocarcionna         LNCaP         ivi         HS         R81. Rap.1         866           9         9         R188. LRAp.1         866         403         403           1         1         R18. LRap.2         403         403           1         1         R18. LRap.2         403         403           1         1         R18. LRap.2         403         403           1         1         1         R18. LRap.2         403         403           1         1         1         1         1         1         474           1         1         1         1         1         1         453           1         1         1         1         1         1         453           1         1         1         1         1         1         1         1<1         1<1           1         1         1         1         1         1         1<1         1<1         1<1         1<1           1         1         1         1         1 <td< th=""><th>SL</th><th>GEO</th><th>Time</th><th>Cancer type</th><th>Cell line</th><th>ORG</th><th>SP</th><th>Condition</th><th># of DRG</th><th># of GRM</th></td<>	SL	GEO	Time	Cancer type	Cell line	ORG	SP	Condition	# of DRG	# of GRM
GSE1864         28         Prostate advocationan         LNCaP         int         HS         R1881_Rep1-1         866           9         29         R1881_Rep1-2         203         R1881_Rep2-2         603           9         1         R1881_Rep2-2         603         605           1         1         R184_Rep1-1         605         606         606           1         1         R184_Rep1-1         805         806         806           1         1         R184_Rep1-1         806         806         806         806           1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1		accession	point							
28         R1811. Rep1.2         9233           9         R1811. Rep1.2         9233           656         Tank. Control of 656         4722           100         Tank. Control of 656         4732           100         Tank. Control of 656         4533           101         Tank. Control of 656         4533           101         Tank. Control of 656         4533           101         Tank. FHC         14764           101         Tank. FHC         14764           101         Tank. FHC         14764           101         Tank. Control of 657         453           101         Tank. Control of 657         453           101         Tank. Control of 657         756           112         Tank. Control of 653         4744           101         Tank. FHC         1574           112         Tank. Control of 653         474           112         Tank. Control of 653         474           112         Tank. Control of 653         474	14	GSE18684	28	Prostate adenocarcinoma	LNCaP	ivr	HS	R1881_Rep1-1	8666	41
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$			28					R1881_Rep1-2	9293	121
9         1134           GSF21618         8         Breast cancer         MGF-7         iv         HS         R188.1.Rep2.2         4032           A         HS         Family LF         Tamk LS         4839         4839           A         HS         Family LF         Tamk LF         4839         4839           A         HS         Family LF         10345         4839         4839           A         HS         MT-E2-Rep1         0345         4839         4839           A         HS         MT-E2-Rep1         0345         4839         4839         4839           A         HS         MT-E2-Rep1         0345         4839         4839         4839         4839         4839         4836         4839         4836         4839         4836         4836         4836         4836         4836         4836         4836         4836         4836         4836         483			9					R1881_Rep2-1	4272	49
$ \begin{array}{lcccccccccccccccccccccccccccccccccccc$			6					R1881_Rep2-2	4052	51
Tank Fac     483       Tank Fac     Tank Fac       Tank Fac     Tank Fac       Tank Fac     1314       Tank Fac     1345       WT_E2_Rep1     0345       WT_E2_Rep1     0345       WT_E2_Rep1     0345       WT_E2_Rep1     0345       WT_E2_Rep1     0345       WT_E2_Rep2     3370       WT_E2_Rep1     039       WT_E2_Rep2     3370       WT_E2_Rep3     330       State     WT_ERC_Rep3       11724     WT_ERC_Rep3       11724     WT_ERC_Rep3       11724     WT_ERC_Rep3       111724     WT_ERC_Rep3       111724     WT_ERC_Rep3       111724     WM       111724     WM       1111724     WM	15	GSE21618	8	Breast cancer	MCF-7	ivr	HS	TamR_Control	6676	47
Tank LRG       1314         Tank LRG       1314         Tank LRG       14764         Tank LRG       14764         Tank LRG       14764         Tank LRG       14764         Tank LRG       10345         WT_E2       7606         WT_E2       7605         WT_E2 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>TamR_E2</td> <td>4859</td> <td>38</td>								TamR_E2	4859	38
Tank HRG       1764         Tank LHRG       10243         WT_E2       8619         WT_E2       870         WT_E2 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>TamR_E2_Tamoxifen</td> <td>11 314</td> <td>36</td>								TamR_E2_Tamoxifen	11 314	36
								TamR_HRG	14~764	38
								TamR_HRG_Tamoxifen	$10\ 243$	31
								TamR_Tamoxifen	10 345	35
								WT_E2	7606	35
GSE41072       19       Acute T cell leukenia       Jurkar or Primary T cells ivr       HS       WT_E2_Tamoxifen       659         GSE41072       19       Acute T cell leukenia       Jurkar or Primary T cells ivr       HS       WT_HRG_Rep2       350         12       WT_HRG_Rep2       353       WT_HRG_Rep2       353       353         13       Skin cancer       Mouse model       ivv       MM       14382         GSE38623       13       Skin cancer       DU145; HT29; MCF7       ivr       HS       11228         GSE38623       13       Skin cancer       DU145; HT29; MCF7       ivr       HS       11228         GSE38623       13       Skin cancer       DU145; HT29; MCF7       ivr       HS       11228         GSE38633       13       Skin cancer       DU145; HT29; MCF7       ivr       HS       11228         GSE38634       8       Breast cancer       DU145; HT29; MCF7       ivr       HS       Hypoxia       632         GSE38641       8       Breast cancer       DU145; HT29; MCF7       ivr       HS       Hypoxia       632         GSE39641       8       Diffuse large B-cell tymphona       HBL-1       ivr       HS       Hypoxia       633 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>WT_E2_Rep1</td> <td>8619</td> <td>39</td>								WT_E2_Rep1	8619	39
GSE41072     19     Acute T cell leukemia     Jurkar or Primary T cells     WT_HRG     639       GSE41072     19     Acute T cell leukemia     Jurkar or Primary T cells     WT_HRG_IRepJ     9274       12     WT_HRG_IRep3     9370       12     WT_HRG_IRep3     9370       12     WT_HRG_IRep3     9330       13     GSE3602     8     Gioblastoma     11 724       12     Mouse whole     iv     MM     1738       13     Skin cancer     Jurkar or Primary T cells     iv     1338       GSE38623     13     Skin cancer     Jurkar Repter     1328       GSE38623     13     Skin cancer     DU145; HT29; MCF7     iv     MM     11 225       GSE29641     8     Breast cancer     DU145; HT29; MCF7     ivr     HS     11 225       GSE29641     8     Diffuse large B-cell lymphoma     HBL-1     ivr     HS     Hypoxia     6325       GSE29641     8     Diffuse large B-cell lymphoma     HBL-1     ivr     HS     Hypoxia     15 278       GSE29641     8     Diffuse large B-cell lymphoma     HBL-1     ivr     HS     Hypoxia     15 278       GSE3044034     8     Diffuse large B-cell lymphoma     HBL-1     ivr								WT_E2_Rep2	3267	41
GSE41072     19     Acute T cell leukenia     Jurkar or Primary T cells     WT_HRG_Rep1     11724       0.03     WT_HRG_Rep2     9274       0.12     WT_HRG_Tamoxifen     603       12     WT_HRG_Tamoxifen     3530       12     WT_HRG_Tamoxifen     3530       13     Skin cancer     Mouse whole     evv     MM       13     Skin cancer     Mouse whole     evv     MM     11225       1328     Glioblastoma     TRP mouse model     ivv     MM     11225       1328     Glioblastoma     TRP mouse model     ivv     MM     11225       1328     Breast cancer     DU145; HT29; MCF7     ivr     HS     Hypoxia     6325       11225     Breast cancer     DU145; HT29; MCF7     ivr     HS     Hypoxia     6325       11225     Breast cancer     DU145; HT29; MCF7     ivr     HS     Hypoxia     6325       11225     Breast cancer     DU145; HT29; MCF7     ivr     HS     Hypoxia     6325       11225     Breast cancer     DU145; HT29; MCF7     ivr     HS     Hypoxia     6325       11225     Breast cancer     DU145; HT29; MCF7     ivr     HS     Hypoxia     6325       1231     Breast cancer <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>WT_E2_Tamoxifen</td> <td>6059</td> <td>37</td>								WT_E2_Tamoxifen	6059	37
GSE41072       19       Acute T cell leukemia       Jurkar or Primary T cells ivr       WT_HRG_Rep2       9274         12       WT_HRG_Rep3       9330       WT_TAmoxifen       6033         12       U       WT_TRG_Rep3       9330         12       U       WT_TRG_Rep3       9330         13       Skin carcer       Mouse wole       ivr       MM       1432         GSE3603       8       Gioblastoma       TRP mouse model       ivr       MM       1432         GSE38633       13       Skin cancer       Mouse whole       evv       MM       1725         GSE38633       13       Skin cancer       Mouse whole       evv       MM       11225         GSE38633       13       Skin cancer       DU145; HT29; MCF7       ivr       HS       Hypoxia       6325         GSE30541       8       Breast cancer       DU145; HT29; MCF7       ivr       HS       Hypoxia       6325         GSE41034       8       Diffuse large B-cell lymphoma       HBL-1       ivr       HS       Hypoxia       7651         GSE41034       8       Diffuse large B-cell lymphoma       HBL-1       ivr       HS       Hypoxia       15278         GSE41034<								WT_HRG	8370	34
GSE41072       19       Acute T cell leukemia       Jurkar or Primary T cells       ivr       HSG_Tamoxifen       5274         12       WT_HRG_Tamoxifen       5330         12       WT_Tamoxifen       5330         12       WT_Tamoxifen       5330         12       WT_Tamoxifen       5330         13       Skin cancer       Mouse whole       ivv       MM       TRPher       1328         GSE3602       8       Breast cancer       DU145; HT29; MCF7       ivr       HS       Hypoxia       603         GSE2602       8       Breast cancer       DU145; HT29; MCF7       ivr       HS       Hypoxia       751         GSE28633       13       Skin cancer       DU145; HT29; MCF7       ivr       HS       Hypoxia       751         GSE29641       8       Diffuse large B-cell lymphoma       HBL-1       ivr       HS       Hypoxia       751         GSE29641       8       Diffuse large B-cell lymphoma       HBL-1       ivr       HS       Hypoxia       751         GSE29641       8       Diffuse large B-cell lymphoma       HBL-1       ivr       HS       Hypoxia       751         GSE29641       8       Diffuse large B-cell lymphoma								WT_HRG_Rep1	11 724	32
GSE41072       19       Acute T cell leukemia       Jurkar or Primary T cells ivr       HS       Jurkat Roc       603         12       WT_Tamoxifen       3530         12       WT_Tamoxifen       3530         12       T cell Roc       8520         GSE3602       8       Globlastoma       TRP mouse model       ivv       MM       TRPhet       1338         GSE38623       13       Skin cancer       Mouse whole       evv       MM       TRPhet       1328         GSE38623       13       Skin cancer       DU145; HT29; MCF7       ivr       HS       Hypoxia       6325         GSE29641       8       Breast cancer       DU145; HT29; MCF7       ivr       HS       Hypoxia       632         GSE29641       8       Diffuse large B-cell lymphoma       HBL-1       ivr       HS       Hypoxia       632         GSE29641       8       Diffuse large B-cell lymphoma       HBL-1       ivr       HS       Hypoxia       632         GSE29641       8       Diffuse large B-cell lymphoma       HBL-1       ivr       HS       Hypoxia       632         GSE29641       8       Diffuse large B-cell lymphoma       HBL-1       HS       Hypoxia       6								WT_HRG_Rep2	9274	42
								WT_HRG_Tamoxifen	6093	35
GSE4107219Acute T cell leukemiaJurkar or Primary T cellsirrHSJurkar Roc14 3821212T cell Roc8520852085208520GSE260028GSE3862313Skin cancerMouse wholeevvMMT R Phet1328GSE3862313Skin cancerMouse wholeevvMMUVB11 225GSE3862313Skin cancerDU145; HT29; MCF7ivrHSHypoxia6325GSE296418Breast cancerDU145; HT29; MCF7ivrHSHypoxia6325GSE296418Diffuse large B-cell lymphonaHBL-1ivrHSHypoxia8169GSE296418Diffuse large B-cell lymphonaHBL-1ivrHSHypoxia8169GSE296418Diffuse large B-cell lymphonaHBL-1ivrHSHypoxia8169GSE410348Diffuse large B-cell lymphonaHBL-1ivrHSHypoxia8169GSE410348Diffuse large B-cell lymphonaHBL-1ivrHSHypoxia8169GSE410348Diffuse large B-cell lymphonaHBL-1ivrHSHypoxia8169GSE410348Diffuse large B-cell lymphonaHBL-1ivrHSHypoxia15 278GSE410348Diffuse large B-cell lymphonaHBL-1ivrHS16 15 278GSE410349HSHSHSHS16 15 278HS <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>WT_Tamoxifen</td> <td>3530</td> <td>37</td>								WT_Tamoxifen	3530	37
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	16	GSE41072	19	Acute T cell leukemia	Jurkar or Primary T cells	ivr	HS	Jurkat Roc	$14 \ 382$	44
GSE260028GlioblastomaTRP mouse modelivvMMTRPhet1328GSE3862313Skin cancerMouse wholeevvMMUVB11225back skinback skin5325GSE296418Breast cancerDU145; HT29; MCF7ivrHSHypoxia6325GSE296418Diffuse large B-cell lymphonaHBL-1ivrHS11225GSE296418Diffuse large B-cell lymphonaHBL-1ivrHS15278GSE410348Diffuse large B-cell lymphonaHBL-1ivrHSIkB kinase15278GSE410348Diffuse large B-cell lymphonaHBL-1ivrHSIkB kinase15278GSE410348Diffuse large B-cell lymphonaHBL-1ivrHSIkB kinase15278GSE410348Diffuse large B-cell lymphonaHBL-1ivrHSIkB kinase15278MLN120BMMMMMMMMMMMLN120BMMMMMMMMMMMLN120BMMMMMMMMMMMLN120BMMMMMMMMMMMLN120BMMMMMMMMMMMMMMMMMMMM			12					Tcell Roc	8520	59
GSE386.2313Skin cancerMouse wholeevvMMUVB11 225back skinback skinback skin663256325GSE296418Breast cancerDU145; HT29; MCF7ivrHSHypoxia6325GSE410348Diffuse large B-cell lymphomaHBL-1ivrHS15 27815 278GSE410348Diffuse large B-cell lymphomaHBL-1ivrHSIkB kinase15 278MLN120BHBL-1ivrHSMLN120BMLN120B15 278	17	GSE26002	8	Glioblastoma	TRP mouse model	ivv	MM	TRPhet	1328	45
GSE29641 8 Breast cancer DU145; HT29; MCF7 ivr HS Hypoxia 6325 Hypoxia 7651 Hypoxia 8169 GSE41034 8 Diffuse large B-cell lymphoma HBL-1 ivr HS like kinase 15278 hypoxia 8169 heta inhibitor MLN120B	18	GSE38623	13	Skin cancer	Mouse whole	evv	MM	UVB	11 225	104
GSE29641 8 Breast cancer DU143; H1.29; MCF/ IVT HS Hypoxia 6.5.25 Hypoxia 7651 Hypoxia 8169 GSE41034 8 Diffuse large B-cell lymphoma HBL-1 ivr HS IkB kinase 15.278 beta inhibitor MLN120B	0		c	ſ	Dack Skill		51.1			ć
GSE41034 8 Diffuse large B-cell lymphoma HBL-1 ivr HS Ik kinase 15 278 beta inhibitor MLN120B	19	GSE29641	×	breast cancer	DU143; H129; MCF/	IVI	EH SH	Hypoxia	6325 7651	20 70
GSE41034 8 Diffuse large B-cell lymphoma HBL-1 ivr HS IkB kinase 15 278 beta inhibitor MLN120B								Hvnoxia	8169	29
beta inhibitor MLN120B	20	GSE41034	×	Diffuse large B-cell lymphoma	HBL-1	ivr	HS	IkB kinase	15 278	4 53
MLN120B								beta inhibitor		
								MLN120B		

Table A1. (Continued)

Table	Table A1. (Continued)								
SL	GEO accession	Time point	Cancer type	Cell line	ORG	SP	Condition	# of DRG	# of GRM
21	GSE23137	16	Breast cancer	MCF-10HER-2	ivr	HS	HER-2 inhibitor CP724,714	11 469	140
22	GSE23138	16	Breast cancer	MCF-10A	ivr	SH	HER-2 inhibitor CP724,714	8811	120
23	GSE23139	16	Breast cancer	MCF-10HER- 2/E7	ivr	SH	HER-2 inhibitor CP724,714	9221	96
24	GSE32869	11	Pancreas adenocarcinoma	AR42J	ivr	RN	Gastrin	7181	81
		12					Control	6594	92
		11					Gastrin	5515	105
25	GSF41491	8 8	Breast cancer	DI1145. HT29. MCF7	Wr	ЯН	Control Hynoxia	6282 6177	144 27
Ì		5					Hypoxia	7406	30
							Hypoxia	8011	24
26	GSE44700	12	B-cell Precursor leukemia cell line	<b>BLaER1</b>	ivr	SH	E2 treatment rep1	31 583	48
							E2 treatment rep2	23 767	68
27	GSE46045	14	Desmoplastic cerebellar medulloblastoma Daoy	ma Daoy	ivr	HS	Control_median	7176	216
							EGF_median	15 659	48
							EGF_SHH_median	17 972	51
							SHH_median	10 770	237
28	GSE49583	8	Pancreatic carcinoma	Primary pan-	ivr	SH	Tumor-cell	4469	48
				creatic stellate			supernatant		
				cells					
29	GSE49584	8	Pancreatic carcinoma	MiaPaca2	ivr	HS	Control	5441	44
30	GSE49586	9	Pancreatic carcinoma	MiaPaca2	ivr	HS	Stellate-cell	14 601	37
							supernatant		
31	GSE50624	8	Acute T cell leukemia	Jurkat	ivr	SH	CDK7 inhibitor	$30\ 013$	9
							CDK7 inhibitor	29804	13

Table	Table A1. (Continued)								
SL	GEO accession	Time point	Cancer type	Cell line	ORG	SP	Condition	# of DRG	# of GRM
32	GSE52710	10	Hodgkin lymphoma	L428	ivr	HS	LNA-antimiR-9	3921	56
							LNA-Scrable	1732	66
33	GSE15327	9	Non-small cell lung cancer	NCI-H1975	ivr	HS	H2O2	2446	75
							Menadione	8912	24
34	GSE50988	23	Osteosarcoma	U2OS	ivr	HS	Thymidine-	7763	792
							nocodazol		
		20					Thymidine rep1	18 894	166
		24					Thymidine rep2	9593	390
		24					Thymidine rep3	24 583	199
35	GSE64073	17	Breast cancer	MCF7	ivr	HS	DHMEQ	20	233
		16					HRG	15533	102
		16					HRG + DHMEQ	16 573	62
		16					HRG +	12 128	174
							LY294002		
		17					LY294002	14 309	48
		17					Control	6427	193
36	GSE71721	11	Burkitt lymphoma	Primary	evv	HS	anti human IgM	6294	58
				lymphoma			F(ab)2 fragment		
							rep1		
		10					anti human IgM	4479	62
							F(ab)2 fragment		
							rep2		
		10					anti human IgM	4479	62
							F(ab)2 fragment		
							rep3		

Table	Table A1. (Continued)								
SL	GEO accession	Time point	Cancer type	Cell line	ORG	SP	Condition	# of DRG	# of GRM
37	GSE15523	8	Skin cancer	BJ NMyc	ivr	HS	N-MycER(delta- MbII)	3875	44
38	GSE17708	6	Lung adenocarcinoma	A549	ivr	SH	N-MycER TGFb1	2741 20 296	54 57
39	GSE18817	8	Diffuse large B-cell lymphoma	HBL-1	ivr	SH	MLN120B	11 865	51
40	GSE34228	26	Lung adenocarcinoma	PC9	ivr	SH	Gefitinib	30 565	73
41	GSE21245	10	Pancreatic adenocarcinoma	LNCaP	ivr	SH	Dihydrotestosterone miRNA arrav	143	188
							Dihydrotestosterone	13 636	93
42	GSE34243	17	N/A	Pgk12.1	ivr	MM	miKNA array Differentiation	343 738	49
43	GSE45958	8	Breast cancer	Control	ivr	SH	2gy Radiation 6ov Radiation	56 560 27191	44 46
7	0/6/2430	0	D			311	Régy	43 650	5 4 5 51
45	GSE84096	0 11	Di casi cancei Non-small cell lung cancer	NCI-H1975	ev ev	SH	EGF	9443	90
		8					Control	7059	64

#### References

- Barrett, T. *et al.* (2012) Ncbi geo: archive for functional genomics data sets-update. *Nucleic acids research*, 41, D991–D995.
- Roberts, K. *et al.* (2017) Information retrieval for biomedical datasets: the 2016 biocaddie dataset retrieval challenge. *Database*, p 2017.
- Chen, X. et al. (2018) Datamed-an open source discovery index for finding biomedical datasets. *Journal of the American Medical Informatics Association*, 25, 300–308.
- Brase, J. (2009) Datacite-a global registration agency for research data. 2009 Fourth International Conference on Cooperation and Promotion of Information Resources in Science and Technology. IEEE, pages 257–261.
- Steuer, R. *et al.* (2002) The mutual information: detecting and evaluating dependencies between variables. *Bioinformatics*, 18, S231–S240.
- Stuart, J.M. *et al.* (2003) A gene-coexpression network for global discovery of conserved genetic modules. *Science*, 302, 249–255.
- Margolin, A.A. *et al.* (2006) Aracne: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. *BMC Bioinformatics*, 7, S7.
- 8. Thomas, R. (1973) Boolean formalization of genetic control circuits. *Journal of theoretical biology*, **42**, 563–585.
- Akutsu, T. *et al.* (2000) Inferring qualitative relations in genetic networks and metabolic pathways. *Bioinformatics*, 16, 727–734.
- Shmulevich, I. *et al.* (2002) Probabilistic boolean networks: a rule-based uncertainty model for gene regulatory networks. *Bioinformatics*, 18, 261–274.
- Bornholdt, S. (2008) Boolean network models of cellular regulation: prospects and limitations. *Journal of the Royal Society Interface*, 5, S85–S94.
- Friedman, N. *et al.* (2000) Using Bayesian networks to analyze expression data. *Journal of Computational Biology*, 7, 601–620.
- 13. Kim, S.Y. *et al.* (2003) Inferring gene networks from time series microarray data using dynamic Bayesian networks. *Briefings in Bioinformatics*, 4, 228–235.
- Zou, M. and Conzen, S.D. (2004) A new dynamic Bayesian network (dbn) approach for identifying gene regulatory networks from time course microarray data. *Bioinformatics*, 21, 71–79.
- 15. Needham, C.J. *et al.* (2007) A primer on learning in Bayesian networks for computational biology. *PLoS computational biology*, **3**, e129.
- Lu, T. *et al.* (2011) High-dimensional odes coupled with mixed-effects modeling techniques for dynamic gene regulatory network identification. *Journal of the American Statistical Association*, 106, 1242–1258.
- Wu, S. *et al.* (2014) Modeling genome-wide dynamic regulatory network in mouse lungs with influenza infection using high-dimensional ordinary differential equations. *PloS one*, 9, e95276.

- Linel, P. et al. (2014) Dynamic transcriptional signatures and network responses for clinical symptoms in influenzainfected human subjects using systems biology approaches. *Journal of Pharmacokinetics and Pharmacodynamics*, 41, 509–521.
- Carey, M. et al. (2018) A big data pipeline: Identifying dynamic gene regulatory networks from time-course gene expression omnibus data with applications to influenza infection. Statistical methods in medical research, 27, 1930–1955.
- Jansen, B. J. et al. (2007) Determining the user intent of web search engine queries. Proceedings of the 16th international conference on World Wide Web. ACM, pages 1149–1150.
- Nunes, B. P. et al. (2013) Combining a co-occurrence-based and a semantic measure for entity linking. Extended Semantic Web Conference. Springer, pages 548–562.
- 22. Ellefi, M. B. et al. (2016) Dataset recommendation for data linking: An intensional approach. European Semantic Web Conference. Springer, pages 36–51.
- Srivastava, K. S., (2018), Predicting and recommending relevant datasets in complex environments. US Patent App. 15/721 122.
- Bollacker, K. D. *et al.* (1998) Citeseer: An autonomous web agent for automatic retrieval and identification of interesting publications. *Proceedings of the second international conference on Autonomous agents*. ACM, pages 116–123.
- Beel, J. *et al.* (2016) Research-paper recommender systems: a literature survey. *International Journal on Digital Libraries*, 17, 305–338.
- Achakulvisut, T. *et al.* (2016) Science concierge: A fast content-based recommendation system for scientific publications. *PloS one*, 11, e0158423.
- 27. Haruna, K. *et al.* (2017) A collaborative approach for research paper recommender system. *PloS one*, **12**, e0184516.
- Beel, J. et al. (2013) Introducing Docear's research paper recommender system. Proceedings of the 13th ACM/IEEE-CS joint conference on Digital libraries. ACM, pages 459–460.
- 29. Wang, C. and Blei, D. M. (2011) Collaborative topic modeling for recommending scientific articles. *Proceedings of the* 17th ACM SIGKDD international conference on Knowledge discovery and data mining. ACM, pages 448–456.
- Huynh, T. et al.(2012) Scientific publication recommendations based on collaborative citation networks. Collaboration Technologies and Systems (CTS), 2012 International Conference on. IEEE, pages 316–321.
- Hur, J. *et al.* (2009) Sciminer: web-based literature mining tool for target identification and functional enrichment analysis. *Bioinformatics*, 25, 838–840.
- Yoneya, T. and Mamitsuka, H. (2007) Pure: a Pubmed article recommendation system based on content-based filtering. *Genome informatics*, 18, 267–276.
- 33. Lin, J. and Wilbur, W.J. (2007) Pubmed related articles: a probabilistic topic-based model for content similarity. *BMC bioinformatics*, **8**, 423.

- Sun, Y. *et al.* (2011) Co-author relationship prediction in heterogeneous bibliographic networks. 2011 International Conference on Advances in Social Networks Analysis and Mining. IEEE, pages 121–128.
- Chen, H.-H. *et al.* (2011) Collabseer: a search engine for collaboration discovery. *Proceedings of the 11th annual international ACM/IEEE joint conference on Digital libraries.* ACM, pages 231–240.
- Tang, J. et al. (2012) Cross-domain collaboration recommendation. Proceedings of the 18th ACM SIGKDD international conference on Knowledge discovery and data mining. ACM, pages 1285–1293.
- 37. Liu, Z. et al. (2018) Context-aware academic collaborator recommendation. Proceedings of the 24th ACM SIGKDD International Conference on Knowledge Discovery & Data Mining. ACM, pages 1870–1879.
- Li, J. *et al.* (2014) Acrec: a co-authorship based random walk model for academic collaboration recommendation. *Proceedings of the 23rd International Conference on World Wide Web.* ACM, pages 1209–1214.

- Huynh, T. et al. (2014) Collaborator recommendation for isolated researchers. 2014 28th International Conference on Advanced Information Networking and Applications Workshops. IEEE, pages 639–644.
- 40. Zhu, Y. *et al.* (2008) Geometadb: powerful alternative search engine for the gene expression omnibus. *Bioinformatics*, 24, 2798–2800.
- 41. Demner-Fushman, D. *et al.* (2017) Metamap lite: an evaluation of a new Java implementation of metamap. *Journal of the American Medical Informatics Association*, 24, 841–844.
- 42. Chen, G. *et al.* (2019) Restructured GEO: restructuring Gene Expression Omnibus metadata for genome dynamics analysis. *Database*, p 2019.
- 43. Patra, B.G. *et al.* (2020) A content-based literature recommendation system for datasets to improve data reusability-a case study on gene expression omnibus (geo) datasets. *Journal of Biomedical Informatics*, page 103399.
- 44. Patra, B.G. *et al.* (2020) A content-based dataset recommendation system for researchers – a case study on gene expression omnibus (geo) repository. *Database*, p 2020.